CCCC logo

CCCCC4 Therapeutics Inc

$3.94
$0.40
(9.22%)
Today
Updated: 03:23 PM EDT
Reported EarningsMay 12
Mkt Cap$479.86M
Vol1.59M
58

Bullish Sentiment

How do you feel about CCCC?

News
all
press releases
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
More News
News Placeholder
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Zacks
News Placeholder
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Zacks
News Placeholder
Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
Vishay Intertechnology (VSH) stock up 10%, Velo3D (VELO) up 35.5%, VNET (VNET) up 32.5%, C4 Therapeutics (CCCC) up 19.4%, Kingsoft Cloud (KC) up 18.6%, Tower Semiconductor (TSEM) up 17.5%, Nebius...
Benzinga
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +4.76% and -5.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling...
MarketBeat
News Placeholder
Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Grows By 19.4%
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 16,157,271 shares, an increase of 19.4% from the March 15th total of 13,534,910 shares. Approximately 18.1% of the...
MarketBeat
News Placeholder
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm...
MarketBeat
<
1
2
...
>